2011
DOI: 10.1007/s13346-011-0043-1
|View full text |Cite
|
Sign up to set email alerts
|

Safety evaluation of chronic intrathecal administration of heparan N-sulfatase in juvenile cynomolgus monkeys

Abstract: An intrathecal (IT) formulation of recombinant human heparan N-sulfatase (HNS) is under development for the treatment of the neurological symptoms of mucopolysaccharidosis IIIA (MPS IIIA; Sanfilippo A disease), the defining clinical feature of this disorder. Since the average age of MPS IIIA patients is 4.5 years, the pivotal toxicology studies for HNS were conducted in juvenile cynomolgus monkeys to evaluate the effects on the developing brain. Monkeys were implanted with an IT-lumbar drug delivery device and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
7
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 18 publications
1
7
0
Order By: Relevance
“…The original clinical trial application was supported by a nonclinical program similar to that described by Pfeifer et al . [ 13 ], and in line with good laboratory practice for nonclinical laboratory studies [ 19 ].…”
Section: Introductionmentioning
confidence: 73%
See 1 more Smart Citation
“…The original clinical trial application was supported by a nonclinical program similar to that described by Pfeifer et al . [ 13 ], and in line with good laboratory practice for nonclinical laboratory studies [ 19 ].…”
Section: Introductionmentioning
confidence: 73%
“…The decrease in LAMP-1 staining observed in the pharmacodynamic comparability study thus serves as a potential indicator of the therapeutic effects of rhASA. Animal studies conducted by other researchers have also yielded safety and activity data for intrathecal drug delivery to the brain, providing further support for this method of administration [ 12 , 13 , 15 , 32 ].…”
Section: Discussionmentioning
confidence: 92%
“…Determining the extent of penetration beyond the site of injection, and in particular, the disposition of rhHNS in the cerebrospinal space with respect to the exposure of specific brain structures or cell types to rhHNS, is important in assessments of therapeutic potential or, conversely, the safety risks of treatment. Previous to the present studies, a safety and tolerability experiment with IT rhHNS in juvenile cynomolgus monkeys found a minimal increase in CNS cellular infiltrates which resolved within one month of the last dose and which were not associated with any adverse clinical signs, gross CNS lesions, or morphological changes in the brain or spinal cord [ 4 ]. A trend in dose-to-rhHNS CSF concentration and to rhHNS activity in CNS tissues was also demonstrated.…”
Section: Discussionmentioning
confidence: 91%
“…Recombinant human heparan N -sulfatase (rhHNS) is an investigatory enzyme replacement therapy (ERT) for the treatment of MPS IIIA. Intravenous (IV) delivery of rhHNS has not demonstrated appreciable CNS penetration needed for therapeutic treatment of the neurocognitive degeneration [ 4 ]. Formulation of rhHNS for intrathecal (IT) administration allows direct delivery to the CNS via the cerebral spinal fluid (CSF).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation